RT Journal Article
SR Electronic
T1 Fractionated Stereotactic Sequential Boost in a Selected Cohort of Glioblastoma Patients: A Mono-institutional Analysis
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 3387
OP 3393
DO 10.21873/anticanres.14322
VO 40
IS 6
A1 ALESSANDRO MARCHIONNI
A1 ISABELLA PALUMBO
A1 GIAMPAOLO MONTESI
A1 VITTORIO BINI
A1 CLAUDIO ZUCCHETTI
A1 NUNZIA CENCI
A1 PIETRO CHIARINI
A1 STEFANO SACCIA
A1 CYNTHIA ARISTEI
A1 MARCO LUPATTELLI
YR 2020
UL http://ar.iiarjournals.org/content/40/6/3387.abstract
AB Aim: To retrospectively assess toxicity and survival in 15 selected Glioblastoma patients treated with a sequential fractionated stereotactic radiotherapy (FSRT) boost after chemo-radiotherapy (CHT-RT) and compare their survival outcomes with a control group. Patients and Methods: Toxicity was assessed with the CTCAE 3.0 scale. The Kaplan-Meier method was used to design survival curves, log-rank test for bivariate analysis and Cox proportional hazard regression model for multivariate analysis. Results: The median follow-up was 16 months (range=5-60). One case of headache and one of radionecrosis (RN) occurred. Median overall survival (OS) was 25 months in the boost group vs. 14 in the no-boost group (p=0.004). Median progression-free survival (PFS) was 15 months in the boost group versus 8 in the no-boost group (p=0.046). At multivariate analysis FSRT boost resulted significantly associated with OS and PFS. Conclusion: In our series a sequential FSRT boost resulted in safe outcomes and significantly associated with survival.